Section 4 Plastic and Reconstructive Problems

TR I NDADE DE ALME I DA ET AL

32. Kane M, Donofrio L, Ascher B, Hexsel D, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel’s assessment and recommendations. J Drugs Dermatol 2010;9:S7–22. 33. Kwiat DM, Bersani TA, Bersani A. Increased patient comfort utilizing botulinum toxin type A reconstituted with preserved versus nonpreserved saline. Ophthalm Plastic Reconstruct Surg 2004;20:186–9. 34. Sarifakioglu N, Sarifakioglu E. Evaluating effects of preservative- containing saline solution on pain perception during botulinum toxin type A injections at different locations: a prospective, single- blinded, randomized controlled trial. Aesth Plast Surg 2005; 29:113–5. 35. Haubner F. Simultaneous injection of lidocaine improves pre- dictability of effect of botulinum toxin. Laryngorrhinootologie 2009;88:764. 36. Kenner JR. Hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for effective and convenient combination aesthetic rejuvenation therapy. J Drug Dermatol 2010;9:1135–8. 37. Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type a reconstituted in lidocaine or in nor- mal saline: a randomized, side-by-side, double-blind study. Br J Dermatol 2007;156:986–9. 38. Li M, Goldberger BA, Carolyn H. Fatal case of Botox s -related anaphylaxis? J Forensic Sci 2005;50:169–72. 39. Hantash BM, Gladstone HB. A pilot study on the effect of epinephrine on botulinum toxin treatment for periorbital rhytides. Dermatol Surg 2007;33:461–8. 40. Redaelli A, Forte R. Botulinum toxin dilution: our technique. J Cosmetic Laser Ther 2003;5:218–9. 41. Le Louarn C. Botulinum toxin A and facial lines: the variable concentration. Aesthet Plast Surg 2001;25:73–84. 42. Yen MT, Wall VK. Bupivacaine-induced myotoxicity and its effect on botulinum toxin paresis. Ann Plast Surg 2008;60:6–9. 43. Moore P, Naumann M. General and clinical aspect of treatment with botulinum toxin. In: Moore P, Naumann M, editors. Hand- book of Botulinum toxin treatment. 2nd edition, Vol. 3. Mass- achussets: Blackwell Science; 2003. p. 41. 44. Bigalke H, Wohlfarth K, Irmer A, Dengler R. Botulinum A toxin: dysport improvement of biological availability. Exp Neurol 2001;168:162–70. 45. Mohammadi B, Kollewe K, Wegener M, Bigalke H, et al. Expe- rience with long-term treatment with albumin-supplemented botulinum toxin type A. J Neural Transm 2009;116:437–41. 46. Toth SI, Smith LA, Ahmed SA. Extreme sensitivity of botulinum neurotoxin domains towards mild agitation. J Pharm Sci 2009;98: 3302–11. 47. Shome D, Nair AG, Kapoor R, Jain V. Botulinum toxin A: is it really a fragile molecule? Dermatol Surg 2010;36: 2106–10. 48. Almeida AT, Kadunc BV, Di Chiacchio N, Neto DR. Foam during reconstitution does not affect the potency of botuinum toxin type A. Dermatol Surg 2003;29:530–1. 49. Kazim NA, Black EH. Botox: shaken, not stirred. Ophtal Plast Reconstr Surg 2008;24:10–2.

14. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformationfor- HeathcareProfessionals/ucm174949.htm (accessed in October 1st, 2010). 15. Package insert on Botox, Irvine, California, USA, Allergan, Inc; October 2010. 16. Package insert on Dysport, Berkshire, UK. Beauford-Ipsen Ltda.; May 2009. 17. Package insert on Prosigne. Distributed by Cristalia in Brazil. Lanzhou, China 2005. 18. Package insert on BTXA, downloaded from www.btxa.com, Lanzhou Institute of Biological Products (LIBP), accessed in Oc- tober 1st. 2010. 19. Package insert on Xeomin, Merz Pharma GmbH & Co, Germany. 2010. 20. Package insert on Myobloc. San Diego, CA: Elan Pharmaceuti- cals; September 2009. 21. Trindade de Almeida AR, kadunc BV, Di Chiacchio N, Neto DR. Foam during reconstitution does not affect the potency of Botulinum toxin A. Dermatol Surg 2003;29:530. 22. Carruthers J, Fagien S, Matarasso SL. Consensus recommenda- tions on the use of botulinum toxin Type A in facial aesthetics. Plast Reconstr Surg 2004;(Suppl);11(6)4:2S. 23. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum toxin A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double blind, randomized controlled trial. Arch Dermatol 2002;138:510. 24. Goodman G. Diffusion and Short-term efficacy of Botulinum toxin A after addition of hyaluronidase and its possible applica- tion for the treatment of axillary hyperhidrosis. Dermatol Surg 2003;29:533–8. 25. Gassner HG, Sherris DA. Addition of an anaesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study. Mayo Clin Proc 2000;75:701–4. 26. Hexsel DM, De Almeida AT, Rutowithsch M, De Castro IA, et al. Multicenter, double blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 2003;29:523. 27. Gartlan MG, Hoffman HT. Cristalline preparation of Botulinum toxin type A (Botox): degradation in potency with storage. Otolaryngol Head Neck Surg 1993;108:135–40. 28. Jabor MA, Kaushik R, Shayani P, Ruiz-Razura A, et al. Efficacy of reconstituted and stored Botulinum toxin Type A: an electro- physiologic study in the auricular muscle of the rabbit. Plast Reconstr Surg 2003;111:2419–26. 29. Greene P. Potency of frozen/thawned botulinum toxin type A in the treatment of torsion dystonia. Otolaryngol Head Neck Surg 1993;109:968–9. 30. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not loose potency in humans if re-frozen or refrig- erated for 2 weeks before use. Neurol 1997;48:149. 31. Thomas JP, Siupsinskiene N. Frozen versus fresh reconstituted botox for laryngeal dystonia. Otolaryngol Head Neck Surg 2006;135:204–8.

3 7 : 1 1 : NOVEMBER 2 0 1 1